Bioluminescence & marine fluorescent proteins

01Overview and value chain

Markers: [EC: Blue biotechnology & European Research Council fluorescence-imaging funding | OECD: Novel biomarker platforms & bio-imaging | Regulator: FDA (US imaging agents), EMA (EU diagnostics), NMPA (China)]

Bioluminescence and marine fluorescent proteins supply the core molecular toolkit for visualizing biological processes in real time, built on two distinct optical mechanisms: bioluminescence (enzymatic luciferin oxidation by luciferase, emitting light with no external excitation needed) and fluorescence (a protein absorbing light at one wavelength and re-emitting it at a longer wavelength, requiring laser or UV excitation). Promega’s NanoLuc platform, an ultra-bright luciferase computationally optimized from a deep-sea shrimp enzyme, continues to anchor new research: a July 2025 study used NanoBiT and NanoBRET tags integrated at endogenous gene loci (EGFR/GRB2, KRas/CRAF) to build regulated protein-protein-interaction reporter cell lines for cancer research, while a January 2026 paper engineered GFP-NanoLuc fusion substrates for sensitive bioluminescence resonance energy transfer (BRET)-based protease-activity detection. Thermo Fisher’s Molecular Probes portfolio remains central to fluorescent-protein innovation: a June 2026 study engineered a photoconvertible fluorescent protein incorporating the noncanonical amino acid p-borono-L-phenylalanine into circularly permuted mEos2 to create a peroxynitrite-responsive sensor, while another June 2026 paper introduced OCaMP, an orange fluorescent genetically encoded calcium indicator with improved two-photon imaging performance for neural-activity studies. ChromoTek (part of Proteintech) continues to expand its nanobody-based affinity toolkit beyond its original GFP-Trap, launching further development of its Spot-Tag system — a compact 12-amino-acid peptide tag paired with a high-affinity Spot-Nanobody — as of an April 2026 product update. In China, a Westlake University team led by Xin Zhang published a major breakthrough in Cell in November 2025, developing a new class of time-resolved fluorescent proteins (tr-FPs) that overcome prior limitations by engineering and regulating fluorescence-lifetime mechanisms, enabling multiplexed imaging distinguished by both color and excited-state lifetime — research supported by multiple National Natural Science Foundation of China grants.

The key directions of bioluminescence and marine fluorescent proteins are:

1. Engineered ultra-bright luciferases: computationally redesigned luciferase enzymes (such as NanoLuc, derived from deep-sea shrimp) delivering far higher signal intensity than classical firefly luciferase for drug-screening assays.
2. Monomeric fluorescent protein engineering: directed evolution and computational design of jellyfish- and coral-derived fluorescent proteins to eliminate oligomerization, increase brightness and shift emission spectra across the full visible-to-near-infrared range.
3. Nanobody-based affinity purification: single-domain llama antibody (VHH) fragments engineered for picomolar-affinity binding to fluorescent-protein tags, enabling ultra-clean immunoprecipitation without classical antibody contamination.
4. Bioluminescence resonance energy transfer (BRET): fusing a luciferase and a fluorescent protein into one construct so luciferin oxidation transfers energy non-radiatively to the fluorophore, creating an ultra-sensitive proximity sensor without external cell illumination.

Sectoral value chain

[Sourcing from bioluminescent/fluorescent marine organisms] ──> [Directed evolution / computational protein design] ──> [Strain development (E. coli/yeast)]
                                                                                                                                    │
                                                                                                                       (Fermentation & downstream purification)
                                                                                                                                    │
     [Commercial research reagents & screening kits] <──── [Formulation & assembly into diagnostic kits] <──────────────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Quantum-chemical chromophore design: computational modeling of electron-density distribution in the chromophore’s conjugated pi-system as influenced by surrounding amino acid residues, letting researchers precisely calculate mutations for a target absorption and emission spectrum.
• Single-domain nanobody affinity reagents (e.g., GFP-Trap): llama-derived single-domain antibody (VHH) fragments with picomolar affinity for GFP, enabling instant, high-purity pulldown of fusion-protein complexes from cell lysates for mass-spectrometry analysis.
• Bioluminescence resonance energy transfer (BRET): integrating a luciferase and fluorescent protein into one construct so luciferin oxidation transfers energy non-radiatively to the fluorophore, used as an ultra-sensitive sensor of molecular proximity without external cell illumination.

02US

The United States leads development of bioluminescent reporter systems for pharmaceutical screening and remains the primary source of advanced fluorescent-protein reagent catalogs.

Promega’s NanoLuc/NanoBRET research pipeline, Thermo Fisher’s photoconvertible and calcium-indicator innovations, NIH high-throughput screening

• Promega Corporation: its NanoLuc luciferase platform continues to anchor new research, including a July 2025 study using NanoBiT/NanoBRET tags at endogenous gene loci for cancer protein-protein-interaction reporter cell lines, and a January 2026 paper engineering GFP-NanoLuc BRET fusion substrates for protease-activity detection.
• Thermo Fisher Scientific (Molecular Probes): a June 2026 study engineered a photoconvertible fluorescent protein incorporating a noncanonical amino acid into circularly permuted mEos2 to create a peroxynitrite-responsive sensor, while another June 2026 paper introduced OCaMP, an improved orange fluorescent calcium indicator for neural-activity imaging.
• NIH high-throughput screening: continues to fund robotic screening systems using fluorescent and bioluminescent sensors to test chemical libraries against cancer and neurodegenerative disease targets across millions of compounds.

03CN

China is building fundamental fluorescent-protein research capability alongside its established bio-imaging equipment manufacturing base.

Westlake University’s time-resolved fluorescent protein breakthrough, Suzhou bio-imaging equipment cluster, aquaculture Lux-biosensors

• Westlake University: a team led by Xin Zhang published a major breakthrough in Cell in November 2025, developing a new class of time-resolved fluorescent proteins (tr-FPs) that overcome prior spectral-crowding limitations by engineering and regulating fluorescence-lifetime mechanisms, enabling multiplexed imaging distinguished by both color and excited-state lifetime.
• Suzhou bio-imaging cluster: the Suzhou Industrial Park has become a center for Chinese optical instrument manufacturing, hosting factories producing laser-scanning confocal microscopes, flow cytometers and macro-imagers for bioluminescent reporter animals, increasingly substituting for expensive American and Japanese equipment.
• Aquaculture biosensors: China is deploying recombinant bacteria with embedded bioluminescent Lux operons to detect trace heavy metals, antibiotics and pesticides in South China Sea coastal waters, with sensor-bacteria luminescence dimming in the presence of contaminants for instant environmental-threat detection.

04EU

The European Union holds strong positions in engineering next-generation monomeric fluorescent proteins and the nanobody-based reagents built on them.

ChromoTek/Proteintech’s expanding nanobody toolkit, Horizon Europe bio-sensing funding, European fluorescent-protein patent licensing

• ChromoTek (part of Proteintech): continues to expand its nanobody-based affinity toolkit beyond its original GFP-Trap and RFP-Trap products, with an April 2026 update detailing further development of its Spot-Tag system — a compact 12-amino-acid peptide tag paired with a high-affinity Spot-Nanobody for antibody-free immunoprecipitation.
• Horizon Europe bio-sensing funding: the European Commission continues to fund multi-million-euro grants to consortia developing wearable and implantable fluorescent sensors for continuous glucose, lactate and blood-gas monitoring, combining optical-protein developers with microfluidic sensor-system engineers.
• European fluorescent-protein patent licensing: European-discovered second-generation monomeric fluorescent proteins (bright variants derived from sea anemones, hydroid polyps and copepods) remain widely licensed to major transnational reagent suppliers, anchoring the region’s position in fluorophore intellectual property.

05Leading companies and research institutes

06Tech stack and innovations

The bioluminescence and marine-fluorescent-protein stack combines advanced optical instrumentation with cell-free and computational protein engineering:

1. Fluorescence lifetime imaging microscopy (FLIM):
   • Advanced laser-scanning systems measure not just fluorophore emission intensity but the nanosecond-scale lifetime of its excited state, letting researchers measure local viscosity, pH and polarity inside a cell independent of overall fluorescent-protein concentration.
2. Multi-detector high-throughput microplate readers:
   • Robotic analyzers equipped with laser diodes and ultra-sensitive photomultiplier tubes simultaneously read FRET, BRET and fluorescence-polarization signals in 384- and 1536-well plate formats at sub-picogram sensitivity.
3. Cell-free protein synthesis systems:
   • Reactor modules using E. coli or wheat-germ lysates assemble and fold fluorescent proteins in vitro, enabling rapid production of labeled toxic proteins whose expression would otherwise kill the living host cell during standard fermentation.

07Value chains and production pipelines

Industrial pipeline for producing high-purity recombinant green fluorescent protein (rGFP) for cell microscopy and calibration (ISO 9001/research grade)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Gene optimization &     │ ───> │ 2. Expression in E. coli   │
│    plasmid cloning              │      │    (IPTG induction, 37°C)      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Ammonium sulfate         │ <─── │ 3. Cell disruption &      │
│    fractionation                │      │    ultracentrifugation          │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Hydrophobic & metal-     │ ───> │ 6. Freeze-drying &         │
│    affinity chromatography      │      │    spectral QC                  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Optimized rGFP gene design and plasmid construction

Bioinformatic analysis of wild-type green fluorescent protein structure guides directed mutagenesis introducing point substitutions (such as S65T and F64L) that sharply increase fluorescence brightness and accelerate chromophore maturation; the codon-optimized gene is chemically synthesized, cloned into a pET-28a plasmid vector under a T7 promoter, with an N-terminal hexahistidine tag added for purification.

Stage 2: Transformation and bioreactor fermentation

The plasmid transforms competent E. coli BL21(DE3) cells; a single colony seeds an LB culture, which is transferred to a 500 L industrial fermenter with glucose-based synthetic media at 37°C; upon reaching OD600 ≈ 6.0, IPTG inducer is added to 0.5 mM and temperature drops to 30°C to reduce inclusion-body formation, with induction continuing for 6 hours before harvest as an emerald-green cell paste.

Stage 3: Cell disruption and extract clarification

Cell paste is suspended in lysis buffer with lysozyme, then continuously pumped through an ultrasonic flow disruptor under ice-bath cooling until over 95% cell lysis is confirmed microscopically; the disrupted mass is ultracentrifuged at 30,000g for 40 minutes to separate cell debris, and the glowing supernatant is decanted.

Stage 4: Primary ammonium sulfate protein fractionation

Solid ammonium sulfate is added to the clarified supernatant to 40% saturation, precipitating host ballast proteins while hydrophilic GFP remains in solution; after removing this precipitate, further ammonium sulfate is added to 75% saturation to precipitate rGFP, which is collected by centrifugation and redissolved in a minimal buffer volume.

Stage 5: Two-stage chromatographic purification (IMAC and HIC)

The redissolved concentrate is desalted by gel filtration, then loaded onto a nickel-affinity (Ni-NTA) column where the His-tagged rGFP binds while ballast proteins wash out and is eluted with high-imidazole buffer; a second hydrophobic-interaction chromatography step (Butyl Sepharose) under high ammonium sulfate further purifies the protein via descending salt gradient, with pure fractions pooled and concentrated by ultrafiltration.

Stage 6: Freeze-drying, final formulation and spectral quality control

The purified protein solution is dialyzed against deionized water with mannitol cryoprotectant, sterile-filtered, filled into glass vials and freeze-dried under deep vacuum, sealed under argon; quality control confirms >99% purity by SDS-PAGE, absorption/emission maxima at 488/509 nm by spectrophotometry, and absence of nuclease/protease contamination before certification as a calibration standard for research institutes.